WO1999014209A1 - Nouveaux derives de taxane - Google Patents
Nouveaux derives de taxane Download PDFInfo
- Publication number
- WO1999014209A1 WO1999014209A1 PCT/JP1998/004180 JP9804180W WO9914209A1 WO 1999014209 A1 WO1999014209 A1 WO 1999014209A1 JP 9804180 W JP9804180 W JP 9804180W WO 9914209 A1 WO9914209 A1 WO 9914209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- salt
- taxane derivative
- hydrogen atom
- Prior art date
Links
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 39
- -1 piperazino Chemical group 0.000 claims abstract description 23
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 5
- 125000002541 furyl group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005484 neopentoxy group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 125000004665 trialkylsilyl group Chemical group 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract description 3
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- KNWCDYSKJSREAQ-UHFFFAOYSA-N 1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)C1NCCO1 KNWCDYSKJSREAQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- YSMYHWBQQONPRD-UHFFFAOYSA-N 2-chlorofuran Chemical compound ClC1=CC=CO1 YSMYHWBQQONPRD-UHFFFAOYSA-N 0.000 description 2
- 229930190007 Baccatin Natural products 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 125000003241 10-deacetylbaccatin III group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NQIBQILAMKZKFE-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)-3-fluoropyridine Chemical compound FC1=CC=C(Br)C=C1C1=NC=CC=C1F NQIBQILAMKZKFE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- NHMSEMKTDAYSGW-QOZDAIMOSA-N Baccatin I Natural products O=C(O[C@H]1[C@H](OC(=O)C)C=2C(C)(C)[C@H]([C@@H](OC(=O)C)[C@@H]3[C@]1(C)[C@H](OC(=O)C)C[C@@H](OC(=O)C)[C@]13OC1)C[C@@H](OC(=O)C)C=2C)C NHMSEMKTDAYSGW-QOZDAIMOSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000025361 Ficus carica Species 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- ORRNUTFGHYJBTG-UHFFFAOYSA-N [2-(2,2-dimethylpropyl)-4-nitrophenyl] hydrogen carbonate Chemical compound CC(C)(C)CC1=CC([N+]([O-])=O)=CC=C1OC(O)=O ORRNUTFGHYJBTG-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a taxane derivative having excellent water solubility and a medicine containing the same (see Background Art).
- (I) is a diterpenoid extracted from the bark of the western yew (Taxus brevifolia), and was isolated and structurally determined for the first time by Wall et al. (J. Am. Chem. So, 1971, 93, 2325). It has been reported to show high efficacy against ovarian and breast cancer (Ann. Int. Med. Ill, 273, 1989).
- taxol is a compound that is hardly soluble in water, it is necessary to use a special solvent in order to formulate it as an injectable drug. Had become.
- an object of the present invention is to provide a novel antitumor activity with improved water solubility.
- An object of the present invention is to provide a specific taxol derivative. Disclosure of the invention
- the present inventors have conducted intensive studies, and found that the solubility of water and the antitumor activity of the taxane (general name of the tachytool skeleton) represented by the following general formula (1) are extremely higher than those of taxol.
- the present invention was found to be highly useful as a pharmaceutical and completed the present invention.
- A is a group —N 1 NR 1 (..., Wherein R 1 represents a hydrogen atom, an alkyl group which may have a substituent: 'a bonyl group)) or
- R 2 represents an amino group, a mono- or di-alkylamino group, or a cyclic amino group
- X represents an alkyl group, a pyridyl group, a cyenyl group, a furyl group, a cycloalkyloxy group, Isopropyloxy group, neopentyloxy group or tert-amyloxy group
- Y represents a hydrogen atom or a trialkylsilyl group
- Ac represents an acetyl group
- B z represents a benzoyl group
- Ph represents a phenyl group.
- the present invention provides a dioxane derivative represented by the formula or a salt thereof.
- the present invention also provides a medicine comprising the taxane derivative represented by the above general formula (1) or a salt thereof as an active ingredient.
- the present invention further provides a taxane derivative represented by the above general formula (1) or a salt thereof. It provides an antitumor agent as an active ingredient.
- the present invention provides a pharmaceutical composition comprising the taxane derivative represented by the general formula (1) or a salt thereof, and a pharmaceutically acceptable carrier. Furthermore, the present invention provides the use of the taxane derivative represented by the above general formula (1) or a salt thereof as a medicament.
- the present invention provides the use of the taxane derivative represented by the above general formula (1) or a salt thereof as an antitumor agent.
- the present invention provides a method for treating a tumor, which comprises administering to a patient an effective amount of the taxane derivative represented by the above general formula (1) or a salt thereof.
- Taxane derivatives of the present invention are those represented by the general formula (1), wherein the alkyl group of the substituent R 1 of the piperazino group among the groups represented by A, carbon number 1-1 0 Alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl, n- Xyl group, n-heptyl group, n-nonyl group and n-decyl group are preferred.
- Alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl, n- Xyl group, n-heptyl group, n-nonyl group and n-decy
- alkyl group examples include a monoalkylaminocarbonyl group and a dialkylaminocarbonyl group. It includes e alkyl ⁇ amino group - and more preferably include 6 alkyl Rua amino group as monoalkyl group, di C is a more preferred dialkyl ⁇ amino group.
- the alkyl moiety of the mono- or di-alkylamino group represented by the substituent R 2 of the piperidino group may be the same as the above-mentioned alkyl group.
- Ethyl, n -propyl, i-ep A mouth pill group is preferred.
- Examples of the cyclic amino group represented by R 2 include a pyrrolidino group, a piperidino group, and a morpholino group.
- particularly preferred groups include dialkylaminopiperidino group, piperidino piperidino group, pyrrolidinobiperidino group, morpholinopiperidino group, and N-alkylpiperazino group.
- alkyl group represented by X the same alkyl groups as those described above for R 1 can be mentioned, and among them, those having 1 to 6 carbon atoms are more preferable.
- cycloalkyloxy group a cycloalkyloxy group having 4 to 6 carbon atoms is preferable, and a cyclopentyloxy group or a cyclohexyloxy group is more preferable.
- the group represented by Y is a hydrogen atom or a trialkylsilyl group, and the trialkylsilyl group includes a tridsalkylsilyl group.
- Y is particularly preferably a hydrogen atom.
- Examples of the salt of the taxane derivative (1) of the present invention include pharmaceutically acceptable salts such as hydrochloric acid, iodide, tartrate, acetate, methanesulfonate, maleate, succinate, and glutarate. And ionic salts such as amino acid salts such as arginine, lysine and alanine.
- the taxane derivative of the present invention or a salt thereof may exist as a hydrate, and the hydrate is also included in the present invention.
- the taxane derivative (1) of the present invention can be produced, for example, according to the following reaction formula.
- R 3 represents a hydrogen atom, an alkoxycarbonyl group or a benzyloxycarbonyl group
- R 4 and R 5 represent a hydrogen atom, alkyl group, show halogenoalkyl group or Arukokishifue two group, rather than when both R 4 and R 5 is a hydrogen atom, and either one force R 4 and R 5, halogenoalkyl group or Arukokishifu nil Group, the other is a hydrogen atom
- Y ' represents a trialkylsilyl group (TES).
- the protection of the hydroxyl group at the 7-position of 10-deacetylbaccatin III is carried out by a known method. That is, it can be carried out by treating with a trialkylunyl chloride in pyridine.
- the protecting group is preferably a trialkylsilyl group, more preferably a tri-C! -Alkylsilyl group, and particularly preferably a triethylsilyl group.
- the hydroxyl group at the 10-position of the compound (3) is acylated to introduce a side chain (A ⁇ ) having a function of imparting water solubility.
- examples of the acylation method include a method using the above-mentioned acid derivative and a method using a condensing agent in the presence of an appropriate base.
- examples of the acylating reagent that can be used include acid chloride, acid anhydride, acid ester, and derivatives equivalent thereto.
- a solvent such as THF is used, and a suitable base (for example, n-butyllithium) is added.
- a method of treating with 4-dimethylaminobiperidinocarbonyl chloride in the presence is used, and a solvent such as THF is used, and a suitable base (for example, n-butyllithium) is added.
- the hydroxyl group at the 13-position is converted to an ester of oxazolidin carboxylic acid to obtain a compound (5).
- This esterification can be carried out, for example, by a derivative of oxazolidinic carboxylic acid, such as N-benzyloxycarbonyl (C bz) —2,2-dimethyl-14-phenyloxy oxazolidinic acid, DCC And dimethylaminopyridine (DMAP).
- the obtained compound (5) is treated with an acid in a solvent such as ethanol to deprotect (de-TES), and then is subjected to catalytic reduction in the presence of palladium-one carbon to obtain an oxazolidine ring. Ring opening can be performed, and compound (6) can be obtained.
- the compound (6) can be converted to the compound (1) of the present invention by acylating the amino group.
- the acylation reaction can be performed using a corresponding acid halide, an acid anhydride or the like in the presence of a condensing agent such as a base.
- the taxane derivative (1) of the present invention had excellent antitumor activity (Test Example 2). And its salts have very high solubility in water (thousands of times that of Takitool), and can be used as pharmaceutical preparations such as injections without using special solvents.
- pharmaceutical preparations injections such as intravenous injection and intramuscular injection are preferred, but in addition to injections, liquid preparations such as inhalants, syrups or emulsions, and solid preparations such as tablets, capsules and granules It can also be formulated into external preparations such as ointments and suppositories.
- these preparations may contain commonly used additives such as auxiliaries, stabilizers, wetting agents, emulsifiers, absorption promoters, or surfactants, if necessary.
- additives include distilled water for injection, Ringer's solution, glucose, sucrose syrup, gelatin, edible oil, cocoa butter, magnesium stearate, and talc.
- the amount of the taxane derivative (1) to be incorporated in each of the above pharmaceutical preparations is not fixed depending on the condition of the patient to which the taxane derivative is to be applied or the dosage form, but generally, the amount of the injection per injection unit is about It is desirable that the amount be 0.5 to 100 mg, about 5 to 100 mg for oral preparations, and about 5 to 100 mg for suppositories.
- the daily dose of the drug having the above dosage form varies depending on the patient's symptoms, weight, age, sex, etc., and cannot be determined unconditionally, but is usually about 0.1 to 50 mgZkg per adult day.
- the dose is preferably about 1 to 2 Omg / kg, which is preferably administered once or twice to four times a day.
- Example 1 Compound a of Example 1 (37 mg, 0.03 country o and 2-thenoyl chloride (4 rag, 0.03 hidden 0) was reacted and worked up in the same manner as in Example 2 to give the title compound ( 8 mg, 26%).
- Example 2 Compound a of Example 1 (37 mg, 0.03 fraction o and isonicotinoyl ⁇ -lide hydrochloride (5 mg, 0.03 thighs, reacted and worked up in the same manner as in Example 2) Thus, the title compound (1.3 mg, 4%) was obtained.
- Example 2 Using compound a of Example 1 (71 mg, 0.06 fraction ⁇ ) and isopropyl chloroformate (7.4 mg, 0.06 country 0), reacted and worked up in the same manner as in Example 2 to give the title. The compound (29 mg, 50%) was obtained.
- Example 7 Using the compound g of Example 7 (7 Omg, 0.06 thigh and neopentyl-p-nitrophenyl carbonate (15 mg, 0.06 concealed 0), the reaction and post-treatment were performed in the same manner as in Example 2. Thus, the title compound (24 mg, 41%) was obtained.
- Example 2 The same reaction and post-treatment as in Example 2 were carried out using the compound g (54 mg, 0.05 o) in Example I and di-tert-amyl dicapalonate (15 mg, 0.06 mmoi). The compound (23 mg, 51%) was obtained.
- Example 12 Using the compound ⁇ (99 mg, 0.08 reference 0) of Example 12 and 2-furyl chloride (7.8 mg, 0.06) in the same manner as in Example 2, The title compound (16 mg, 19%) was obtained.
- Example 12 Using the compound of Example 2 (60 mg, 0.05 fraction o), 3-fluoroacid (7.8 mg, 0.06%) and DCC (0.06%), The reaction and work-up were conducted in the same manner as in 2, to give the title compound (13 mg, 26%).
- Solubility test of compound (b) weigh 4.Omg of compound (b) and use purified water 2.0 The suspension was mixed with 0. IN-hydrochloric acid (4.5 ⁇ , 1.05 eq.) And treated with ultrasonic waves to form a uniform suspension and shaken at room temperature for 2 hours. The mixture was filtered using a membrane filter (0.22 m), and the filtrate was used as a sample solution. The test was performed on the sample solution by the HPLC method (operating condition 1). The solubility of the compound (b) was determined from the area obtained as the average of three measurements.
- UV absorption spectrophotometer (225nm), 0.2auis
- Solubility test of compound (j) weigh 4.24 mg of compound (j), suspend in purified water 2. Add 0.1-hydrochloric acid 46 (1.0 eq.) To this suspension. In addition, the suspension was sonicated to form a uniform suspension and shaken at room temperature for 2 hours. The mixture was filtered using a membrane filter (0.22 m), and the filtrate was used as a sample solution. The sample solution was tested by the HPLC method (operating condition 1). The average of three measurements The solubility of the compound (j) was determined from the area thus obtained.
- KB Human oral cancer-derived KB cells were purchased from Dainippon Pharmaceutical Co., Ltd. and used as cryopreserved at our institute.
- KB is 1 0% ⁇ Shi Du Lbecco containing calf serum 's mod ified E arg 1 es me di um ( ⁇ Pharmaceutical (Ltd.)), 5%, C0 2 - cultured under conditions of air, 37 ° C , Maintained.
- Each compound was dissolved in DMSO to a concentration of 1 Omg ⁇ before use.
- Cells in the logarithmic growth phase are placed on Day-1 at 200 Ocells / 100 ⁇ i / well and placed on 96-well microplates (Falcon ⁇ 3072).
- the cells were inoculated using a phenol red-free medium (Du1 becco's modified Eagle's medium (Sigma)) containing 10% fetal bovine serum, and cultured in the oocytes.
- a phenol red-free medium Du1 becco's modified Eagle's medium (Sigma)
- fetal bovine serum fetal bovine serum
- Each compound diluted with the same culture solution was added to each well in a volume of 100 ⁇ so that the daily concentration was 0.03 to 10,000 ngZ ⁇ per day 0, and the cells were cultured for 3 days.
- a 3-well volume was used for each drug concentration, and a blank 3-well volume containing only the culture solution was provided for each plate, and an 8-well volume was provided as a drug-untreated control.
- XTT (Sigma) was dissolved in a serum-free culture solution at a concentration of 1 nigZ, and phenodine metha-fate (Sigma) dissolved in PBS at a concentration of 5 mM was added to 1 Z200 volume. added. This was added to each well in an amount of 50 ⁇ l, and after culturing for 4 hours, 0 D was measured at 450 nm using ELISA.
- GI 5 ⁇ was calculated from the concentration-growth inhibition rate ( GIR ) curve by interpolation. However, GIR was calculated by the following equation.
- the taxane derivative of the present invention has a very high solubility in water of several thousand times that of tachytool, it can be used as a liquid preparation such as an injection without using a special solvent and has excellent antitumor activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69809959T DE69809959T2 (de) | 1997-09-17 | 1998-09-17 | Neue taxanderivate |
AT98943019T ATE229012T1 (de) | 1997-09-17 | 1998-09-17 | Neue taxanderivate |
DK98943019T DK1022277T3 (da) | 1997-09-17 | 1998-09-17 | Nye taxanderivater |
BR9812218-5A BR9812218A (pt) | 1997-09-17 | 1998-09-17 | Novos derivativos de taxane |
EP98943019A EP1022277B1 (en) | 1997-09-17 | 1998-09-17 | New taxane derivatives |
AU90950/98A AU730174B2 (en) | 1997-09-17 | 1998-09-17 | Novel taxane derivatives |
CA002302445A CA2302445C (en) | 1997-09-17 | 1998-09-17 | New taxane derivatives |
US09/508,092 US6136808A (en) | 1997-09-17 | 1998-09-17 | Taxane derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9251804A JPH1192468A (ja) | 1997-09-17 | 1997-09-17 | 新規なタキサン誘導体 |
JP9/251804 | 1997-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999014209A1 true WO1999014209A1 (fr) | 1999-03-25 |
Family
ID=17228181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004180 WO1999014209A1 (fr) | 1997-09-17 | 1998-09-17 | Nouveaux derives de taxane |
Country Status (14)
Country | Link |
---|---|
US (1) | US6136808A (ja) |
EP (1) | EP1022277B1 (ja) |
JP (1) | JPH1192468A (ja) |
KR (1) | KR100514809B1 (ja) |
CN (1) | CN100369908C (ja) |
AT (1) | ATE229012T1 (ja) |
AU (1) | AU730174B2 (ja) |
BR (1) | BR9812218A (ja) |
CA (1) | CA2302445C (ja) |
DE (1) | DE69809959T2 (ja) |
DK (1) | DK1022277T3 (ja) |
ES (1) | ES2189234T3 (ja) |
PT (1) | PT1022277E (ja) |
WO (1) | WO1999014209A1 (ja) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057033A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes as antitumor agents |
WO2001057013A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | Taxane formulations having improved solubility |
JP2003055360A (ja) * | 2001-07-31 | 2003-02-26 | Florida State Univ Research Foundation Inc | C10エステル置換タキサン |
US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
EP1982720A1 (en) | 2002-05-20 | 2008-10-22 | The Regents of the University of California | Ribaviren for use to treat cancer |
US7589111B2 (en) | 2004-02-13 | 2009-09-15 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
EP2108362A2 (en) | 2002-06-26 | 2009-10-14 | Medigene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
WO2010035985A2 (ko) * | 2008-09-26 | 2010-04-01 | 동아제약 주식회사 | 탁산 유도체의 제조방법 |
JP2011517455A (ja) * | 2008-03-31 | 2011-06-09 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | C(10)エチルエステルおよびc(10)シクロプロピルエステル置換タキサン |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
EP3056196A1 (en) | 2006-03-22 | 2016-08-17 | SynCore Biotechnology CO., LTD | Treatment of triple receptor negative breast cancer |
WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
WO2017115301A1 (en) | 2015-12-30 | 2017-07-06 | Syncore Biotechnology Co., Ltd. | Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent |
WO2017178456A1 (en) | 2016-04-11 | 2017-10-19 | Greenaltech, S.L | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2018017190A2 (en) | 2016-06-01 | 2018-01-25 | Baxalta Incorporated | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
EP3300745A1 (en) | 2013-02-15 | 2018-04-04 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
WO2018127082A1 (en) | 2017-01-05 | 2018-07-12 | Syncore Biotechnology Co., Ltd. | Treatment of pancreatic cancer |
WO2018136570A1 (en) | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
US10640563B2 (en) | 2016-06-08 | 2020-05-05 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2021155028A1 (en) | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
WO2021247423A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2022051390A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
EP4218929A1 (en) | 2014-03-21 | 2023-08-02 | AbbVie Inc. | Anti-egfr antibodies and antibody drug conjugates |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
US11759527B2 (en) | 2021-01-20 | 2023-09-19 | Abbvie Inc. | Anti-EGFR antibody-drug conjugates |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU758418B2 (en) * | 1997-12-19 | 2003-03-20 | Kabushiki Kaisha Yakult Honsha | Taxane derivatives |
JP2003502290A (ja) * | 1999-05-28 | 2003-01-21 | ブリストル−マイヤーズ スクイブ カンパニー | ジアルキルジクロロシランを用いるパクリタキセルの半合成 |
US20060189679A1 (en) * | 2005-02-14 | 2006-08-24 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
KR100847331B1 (ko) * | 2006-12-14 | 2008-07-21 | 한미약품 주식회사 | 도세탁셀의 제조방법 및 이에 사용되는 중간체 |
WO2010005721A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
WO2013119864A1 (en) | 2012-02-07 | 2013-08-15 | University Of Central Florida Research Foundation, Inc. | Increasing taxane sensitivity in cancer cells |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
WO2015149001A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03505725A (ja) * | 1988-03-07 | 1991-12-12 | アメリカ合衆国 | 水溶性抗腫瘍性タキソール誘導体 |
JPH05239055A (ja) * | 1991-09-23 | 1993-09-17 | Univ Florida | 新規なフリル及びチエニル置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH05239044A (ja) * | 1991-09-23 | 1993-09-17 | Univ Florida | 新規なアルコキシ置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH06199824A (ja) * | 1991-09-23 | 1994-07-19 | Univ Florida | 新規な置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH07503477A (ja) * | 1992-02-07 | 1995-04-13 | ローン−プーラン・ロレ・ソシエテ・アノニム | バッカチン3および10‐デアセチルバッカチン3の新規誘導体,それらの製造およびそれらを含有する医薬組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08253465A (ja) * | 1995-03-17 | 1996-10-01 | Dai Ichi Seiyaku Co Ltd | 四環性化合物 |
FR2742753B1 (fr) * | 1995-12-22 | 1998-01-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
CN1097044C (zh) * | 1996-07-15 | 2002-12-25 | 亚库尔特株式会社总社 | 紫杉烷衍生物以及含有该衍生物的药物 |
US6017935A (en) * | 1997-04-24 | 2000-01-25 | Bristol-Myers Squibb Company | 7-sulfur substituted paclitaxels |
-
1997
- 1997-09-17 JP JP9251804A patent/JPH1192468A/ja active Pending
-
1998
- 1998-09-17 DE DE69809959T patent/DE69809959T2/de not_active Expired - Fee Related
- 1998-09-17 AU AU90950/98A patent/AU730174B2/en not_active Ceased
- 1998-09-17 KR KR10-2000-7002637A patent/KR100514809B1/ko not_active IP Right Cessation
- 1998-09-17 PT PT98943019T patent/PT1022277E/pt unknown
- 1998-09-17 AT AT98943019T patent/ATE229012T1/de not_active IP Right Cessation
- 1998-09-17 ES ES98943019T patent/ES2189234T3/es not_active Expired - Lifetime
- 1998-09-17 DK DK98943019T patent/DK1022277T3/da active
- 1998-09-17 CN CNB988092395A patent/CN100369908C/zh not_active Expired - Fee Related
- 1998-09-17 US US09/508,092 patent/US6136808A/en not_active Expired - Fee Related
- 1998-09-17 CA CA002302445A patent/CA2302445C/en not_active Expired - Fee Related
- 1998-09-17 BR BR9812218-5A patent/BR9812218A/pt not_active Application Discontinuation
- 1998-09-17 EP EP98943019A patent/EP1022277B1/en not_active Expired - Lifetime
- 1998-09-17 WO PCT/JP1998/004180 patent/WO1999014209A1/ja active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03505725A (ja) * | 1988-03-07 | 1991-12-12 | アメリカ合衆国 | 水溶性抗腫瘍性タキソール誘導体 |
JPH05239055A (ja) * | 1991-09-23 | 1993-09-17 | Univ Florida | 新規なフリル及びチエニル置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH05239044A (ja) * | 1991-09-23 | 1993-09-17 | Univ Florida | 新規なアルコキシ置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH06199824A (ja) * | 1991-09-23 | 1994-07-19 | Univ Florida | 新規な置換されたタキサン及びそれらを含有する薬剤組成物 |
JPH07503477A (ja) * | 1992-02-07 | 1995-04-13 | ローン−プーラン・ロレ・ソシエテ・アノニム | バッカチン3および10‐デアセチルバッカチン3の新規誘導体,それらの製造およびそれらを含有する医薬組成物 |
Non-Patent Citations (1)
Title |
---|
KANT J., ET AL.: "A CHEMOSELECTIVE APPROACH TO FUNCTIONALIZE THE C-10 POSITION OF 10-DEACETYLBACCATIN III. SYNTHESIS AND BIOLOGICAL PROPERTIES OF NOVEL C-10 TAXOL ANALOGUES.", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 35., no. 01., 1 January 1994 (1994-01-01), GB, pages 5543 - 5546., XP002915065, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)77242-X * |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524869B2 (en) | 2000-02-02 | 2009-04-28 | Florida State University Research Foundation, Inc. | Taxanes having a C10 ester substituent |
WO2001057013A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | Taxane formulations having improved solubility |
US6596737B2 (en) | 2000-02-02 | 2003-07-22 | Fsu Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes |
US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
US6906088B2 (en) | 2000-02-02 | 2005-06-14 | Fsu Research Foundation, Inc. | Taxanes having a C10 carbamoyloxy substituent |
US7230013B2 (en) | 2000-02-02 | 2007-06-12 | Florida State University Research Foundation, Inc. | C10 carbamoyloxy substituted taxane compositions |
WO2001057033A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes as antitumor agents |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6869973B2 (en) | 2000-06-22 | 2005-03-22 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
JP2003055360A (ja) * | 2001-07-31 | 2003-02-26 | Florida State Univ Research Foundation Inc | C10エステル置換タキサン |
EP1285920A1 (en) * | 2001-07-31 | 2003-02-26 | Florida State University Research Foundation, Inc. | C10 Ester sustituted taxanes as antitumor agents |
EP1982720A1 (en) | 2002-05-20 | 2008-10-22 | The Regents of the University of California | Ribaviren for use to treat cancer |
EP2108362A2 (en) | 2002-06-26 | 2009-10-14 | Medigene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US9238021B2 (en) | 2002-06-26 | 2016-01-19 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US8663606B2 (en) | 2002-06-26 | 2014-03-04 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US7794747B2 (en) | 2002-06-26 | 2010-09-14 | Medigene Oncology Gmbh | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
EP2277507A1 (en) | 2002-06-26 | 2011-01-26 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
EP2286795A1 (en) | 2002-06-26 | 2011-02-23 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US8075913B2 (en) | 2002-06-26 | 2011-12-13 | Medigene Ag | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7589111B2 (en) | 2004-02-13 | 2009-09-15 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
US8003812B2 (en) | 2004-02-13 | 2011-08-23 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
EP3056196A1 (en) | 2006-03-22 | 2016-08-17 | SynCore Biotechnology CO., LTD | Treatment of triple receptor negative breast cancer |
JP2011517455A (ja) * | 2008-03-31 | 2011-06-09 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | C(10)エチルエステルおよびc(10)シクロプロピルエステル置換タキサン |
US8242166B2 (en) | 2008-03-31 | 2012-08-14 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes |
EP2859916A2 (en) | 2008-05-22 | 2015-04-15 | Galera Therapeutics, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
WO2010035985A2 (ko) * | 2008-09-26 | 2010-04-01 | 동아제약 주식회사 | 탁산 유도체의 제조방법 |
WO2010035985A3 (ko) * | 2008-09-26 | 2010-06-17 | 동아제약 주식회사 | 탁산 유도체의 제조방법 |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
EP4303232A2 (en) | 2013-02-15 | 2024-01-10 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
EP3300745A1 (en) | 2013-02-15 | 2018-04-04 | The Regents of the University of California | Chimeric antigen receptor and methods of use thereof |
EP3613439A1 (en) | 2013-02-15 | 2020-02-26 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
EP3881868A1 (en) | 2013-02-15 | 2021-09-22 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
EP4218929A1 (en) | 2014-03-21 | 2023-08-02 | AbbVie Inc. | Anti-egfr antibodies and antibody drug conjugates |
WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
WO2017115301A1 (en) | 2015-12-30 | 2017-07-06 | Syncore Biotechnology Co., Ltd. | Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent |
WO2017178456A1 (en) | 2016-04-11 | 2017-10-19 | Greenaltech, S.L | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US11788066B2 (en) | 2016-04-26 | 2023-10-17 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2018017190A2 (en) | 2016-06-01 | 2018-01-25 | Baxalta Incorporated | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
EP4019007A1 (en) | 2016-06-01 | 2022-06-29 | Servier IP UK Limited | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
WO2017214458A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
US10640563B2 (en) | 2016-06-08 | 2020-05-05 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2018127082A1 (en) | 2017-01-05 | 2018-07-12 | Syncore Biotechnology Co., Ltd. | Treatment of pancreatic cancer |
WO2018136570A1 (en) | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
WO2020206033A1 (en) | 2019-04-02 | 2020-10-08 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2021155028A1 (en) | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
WO2021247423A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2022051390A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
WO2022103603A1 (en) | 2020-11-13 | 2022-05-19 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
US11759527B2 (en) | 2021-01-20 | 2023-09-19 | Abbvie Inc. | Anti-EGFR antibody-drug conjugates |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Also Published As
Publication number | Publication date |
---|---|
EP1022277B1 (en) | 2002-12-04 |
DE69809959D1 (de) | 2003-01-16 |
US6136808A (en) | 2000-10-24 |
PT1022277E (pt) | 2003-04-30 |
CA2302445C (en) | 2008-04-29 |
JPH1192468A (ja) | 1999-04-06 |
AU730174B2 (en) | 2001-03-01 |
DK1022277T3 (da) | 2003-01-06 |
CN100369908C (zh) | 2008-02-20 |
KR20010023937A (ko) | 2001-03-26 |
ATE229012T1 (de) | 2002-12-15 |
AU9095098A (en) | 1999-04-05 |
BR9812218A (pt) | 2000-07-18 |
KR100514809B1 (ko) | 2005-09-13 |
EP1022277A4 (en) | 2000-07-26 |
EP1022277A1 (en) | 2000-07-26 |
CN1270587A (zh) | 2000-10-18 |
ES2189234T3 (es) | 2003-07-01 |
CA2302445A1 (en) | 1999-03-25 |
DE69809959T2 (de) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999014209A1 (fr) | Nouveaux derives de taxane | |
WO1998002426A1 (fr) | Derives de taxane et medicaments les contenant | |
Sin et al. | Eponemycin analogues: syntheses and use as probes of angiogenesis | |
CN102391359B (zh) | 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途 | |
CZ298484B6 (cs) | Taxan a farmaceutická kompozice s jeho obsahem | |
WO1999032473A1 (fr) | Derives de taxane | |
EP2233467B1 (en) | Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof | |
CN101903337A (zh) | 抗肿瘤化合物 | |
Ojima et al. | Structure–activity relationship study of taxoids for their ability to activate murine macrophages as well as inhibit the growth of macrophage-like cells | |
JPH10500394A (ja) | 多重薬剤耐性細胞を抗腫瘍剤に対して感受性にするための多環式ラクタム誘導体 | |
CN109134511B (zh) | C19位氟代的Largazole类似物、其制备方法和用途 | |
CN107365351B (zh) | 海洋天然产物内酰胺型Largazole类似物、其制备方法和用途 | |
US7160919B2 (en) | C7 lactyloxy-substituted taxanes | |
RU2419622C2 (ru) | Производные таксола с противоопухолевой активностью | |
AU2002328942B2 (en) | C-2' methylated derivatives of paclitaxel for use as antitumour agents | |
JP2964474B2 (ja) | タキソール誘導体及びその製法 | |
JP2005500365A (ja) | 抗腫瘍剤としての使用のためのパクリタキセルのc−2′メチル化誘導体 | |
JPH09235225A (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98809239.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2302445 Country of ref document: CA Ref document number: 2302445 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 90950/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998943019 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007002637 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09508092 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998943019 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007002637 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 90950/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998943019 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007002637 Country of ref document: KR |